Royalty Report: Drugs, Delivery, Pain – Collection: 319229

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Delivery
  • Pain
  • Cannabis
  • Drug Discovery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 319229

License Grant
United Kingdom Licensor granted to the Licensee an exclusive world-wide license to develop and commercialize products, including NES100, which contain hydrophilic neuropeptide Leucin5-Enkephalin and an amphiphile compound which is quaternary ammonium palmitoyl glycol chitosan, and to engage in a collaborative program utilizing Licensors knowledge, skills and expertise in the clinical development of products and in attracting external funding for such development.
License Property
NES100 is a nanotechnology-based intranasal spray drug product candidate which enables the delivery of a metabolically labile peptide drug (Enkephalin) into the brain. NES100 is manufactured using high pressure homogenization and spray drying. The Molecular Envelope Technology (MET) nanoparticles are well tolerated via the nasal route at the dose administered. There is pharmacological evidence of activity of MET enabled enkephalin in morphine-tolerant animals.  NES100 is an intranasal device to deliver exogenous enkephalin for the management of acute and chronic pain containing hydrophilic neuropeptide Leucin5-Enkephalin and an amphiphile compound which is quaternary ammonium palmitoyl glycol chitosan.

Intellectual Property includes but not limited to the US Patent Nos. 8,278,277.  This covers lipophilic derivatives of hydrophilic drugs comprising a hydrophilic drug and a cleavable linker as well as methods of treatment using these compositions. In particular the patents relate to compositions of a lipophilic derivative of the hydrophilic neuropeptide Leucine [5]-Enkephalin and an amphiphile compound, where the derivative includes a lipophilic linker attached to the side chain oxygen of the tyrosine in the Leucine [5]-Enkephalin, and where the amphiphile compound is quaternary palmitoyl glycol chitosan (GCPQ).
8,278,277 – Delivery of hydrophilic drugs

Licensor is a leader in pharmaceutical nanotechnology. The nanomedicines know-how and proprietary technology platforms provide drug delivery solutions for poorly water soluble drugs, nucleic acids and peptides.

Field of Use
The field of use is for the management of Post-Traumatic Stress Disorder relating to pain.  NES100 is an intranasal device and using this product supports the effort among prescribers, regulators, and patients to seek non-addictive treatment options to combat the opioid epidemic.

IPSCIO Record ID: 377097

License Grant
Licensee entered into a collaboration with Licensor of the United Kingdom for the exclusive worldwide license to develop and commercialize an investigational formulation delivered via the nasal route to enhance pharmaceutical-grade cannabidiol (CBD) transport to the brain to potentially treat seizures associated with tuberous sclerosis complex (TSC),
License Property
VRP324, the first investigational formulation delivered via the nasal route to enhance CBD transport to the brain. VRP324 uses a preassembled device and cartridge to propel the CBD powder formulation into the nose to the brain via the olfactory nerve/bulb.

VRP324 is a drug product candidate based on nanotechnology which enables the delivery of CBD into the brain via intranasal delivery for the management of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older, as well as patients one year of age and older who experience seizures associated with Lennox-Gastaut syndrome ( LGS) or Dravet syndrome. VRP324 is manufactured using high pressure homogenization and spray drying. In animal studies, the MET nanoparticles are well-tolerated via the nasal route at the dose administered.

Field of Use
The rights are to use Licensor’s molecular envelope platform technology (MET) for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children.

Field of use is for the treatment of seizures associated with tuberous sclerosis complex (TSC)  Lennox-Gastaut syndrome and Dravet syndrome in patients one year of age and older.

Lennox-Gastaut syndrome and Dravet syndrome are rare central nervous system diseases considered serious epileptic encephalopathies that cause different types of epileptic seizures as well as cognitive and behavioral changes and are generally resistant to treatment.

Tuberous sclerosis complex (TSC) is a hereditary condition associated with changes in the skin, brain, kidney, and heart. Seizures are a frequent complication, and some people with TSC have learning disabilities. Skin changes are the most noticeable sign of TSC and appear in nearly all people with the condition.

IPSCIO Record ID: 372482

License Grant
Licensor grants an exclusive, including with respect to Licensor except as to Licensor’s performance of its obligations under this Agreement or conduct of the Existing Clinical Trials, license, with the right to sublicense, in the Field in the Territory, under the Licensor Intellectual Property, to develop, make or have made, use, offer for sale, sell, import, market and promote Product.

For the Licensor Trademarks, Licensor grants an exclusive, including with respect to Licensor except as to Licensor’s performance of its obligations under this Agreement and conduct of Existing Clinical Trials, license, with the right to sublicense, to use the Licensor Trademarks solely in connection with Product in the Territory.

License Property
The patents relate to
Transmucosal delivery devices with enhanced uptake;
Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces; and,
Transmucosal drug delivery for use in chronic pain relief.

Licensor controls certain patents and know-how relating to Product, and has initiated clinical studies with respect to the Product.

The Active Ingredient means buprenorphine.  Buprenorphine is an opioid used to treat opioid use disorder, acute pain, and chronic pain.

Product means a drug product containing buprenorphine as its sole active ingredient (and not containing naloxone or any analog or derivative thereof and using Licensors BEMA Technology in any formulation and any dosage strength.

BEMA Technology means Licensor’s proprietary BioErodible MucoAdhesive (BEMA®) Drug Delivery Technology, a buccal soluble film consisting of a small bioerodible polymer film for application to the mucosal membranes (inner lining of the cheek).

Field of Use
The Field means all uses in humans.  Buprenorphine is an opioid used to treat opioid use disorder, acute pain, and chronic pain.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.